Category CELL THERAPY

PIER MARIA FORNASARI
2026-03-05

Cloaked Stem Cells Evade Immune Rejection in Mice, Pointing to a Potential Universal Donor Cell Line

A study published today in Stem Cell Reports demonstrates that genetically engineered human pluripotent stem cells (hPSCs) can overcome immune rejection in mice with humanized immune systems, surviving for five months in a stringent transplantation model. The findings provide proof-of-principle for the development of a potential universal donor hPSC line designed to resist immune attack. Led by Danny Chan,

Read More

No Comments InCELL THERAPY iPS cells REGENERATIVE MEDICINE
PIER MARIA FORNASARI
2026-02-14

Cell and gene therapy across 35 years

Cell and gene therapies, or CGT, have come a long way since they were first introduced. In the last few decades, both cell therapy — the transplantation of living cells — and gene therapy — the use of genetic material to modify cell functions — have been increasingly incorporated into clinical practice. Various challenges and advances

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT CELL THERAPY GENE THERAPY RARE DISEASES REGENERATIVE MEDICINE
PIER MARIA FORNASARI
2026-01-25

ISSCR Develops Roadmap to Accelerate Pluripotent Stem Cell-Derived Therapies to Patients

“Charting the Translational Pathway: ISSCR Best Practices for the Development of PSC-Derived Therapies,” offers insights into the comprehensive, globally informed guide to navigating the complex journey from laboratory discovery to approved therapy. The International Society for Stem Cell Research (ISSCR) today announced the upcoming release of “Charting the Translational Pathway: ISSCR Best Practices for the

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2025-12-10

FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia

The U.S. Food and Drug Administration announced it has approved Omisirge (omidubicel-onlv), the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with severe aplastic anemia (SAA). Omisirge is indicated for adults and pediatric patients 12 years and older with hematologic malignancies and now is approved for adults and pediatric patients six years and

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2025-12-07

Partial Match Parity: Increasing the Donor Pool for Hematopoietic Stem Cell Transplantation

Blood cancer patients who may have previously struggled to find a donor for transplantation now have more options. A new study shows that patients achieve good outcomes with an partial match drawn from the national public registry of donors when they are treated with the immune-suppressing drug cyclophosphamide. Survival rates at one year were on par

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2025-03-06

Cultured tissue from nasal cartilage cells helps with complicated knee injuries

Damage to joint cartilage is painful and limits mobility. Researchers at the University of Basel and the University Hospital of Basel are therefore developing cartilage implants from cells from the nasal septum. A recent study shows that a longer maturation time for the cultured cartilage brings a significant improvement even in cases of complicated cartilage

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2024-03-14

A micro-fragmented collagen gel as a stem cell-assembling platform for critical limb ischemia repair

Critical limb ischemia is a condition in which the main blood vessels supplying blood to the legs are blocked, causing blood flow to gradually decrease as atherosclerosis progresses in the peripheral arteries. It is a severe form of peripheral artery disease that causes progressive closure of arteries in the lower extremity, leading to the necrosis

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2023-11-14

Study Shows Stem Cell Transplant Significantly Improves Outcomes in Refractory Juvenile Systemic Sclerosis

New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that patients with refractory juvenile systemic sclerosis improved significantly on nearly all measures for two years following autologous stem cell transplant (Abstract #L06). Juvenile-onset systemic sclerosis (jSSc), also called scleroderma, is a disfiguring autoimmune disorder marked by hardening of the skin

Read More

No Comments InAUTOIMMUNE DISEASES CELL THERAPY
PIER MARIA FORNASARI
2023-11-07

New study findings call into question the superiority of stem cell therapy for treating knee pain

Characterized by extensive damage to joints and debilitating pain, osteoarthritis (OA) impacts millions of people worldwide and has long posed a substantial clinical and economic burden. In spite of advances in diagnosis, medications, and short-term pain management solutions, the elusive goal of a disease-modifying OA drug has remained out of reach. In recent years though,

Read More

No Comments InCELL THERAPY REGENERATIVE MEDICINE
PIER MARIA FORNASARI
2023-09-20

The use of cell therapy to treat COVID-19 patients can reduce the risk of death from the disease by 60%, according to a systematic review and meta-analysis conducted by researchers at the University of São Paulo (USP) in Brazil, in partnership with colleagues in Germany and the United States.

Brazilian researchers and collaborators in Germany and the US compiled data from 195 clinical trials conducted in 30 countries between January 2020 and December 2021. The findings are promising, although the authors stress the need for enhanced controls in the making of the products used in cell therapy. Their findings are reported in an article

Read More

No Comments InCELL THERAPY Covid-19